Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
10.1139/apnm-2020-0005 Appl
Unexpectedly, targeting ACLY (SB-204990), Acetyl-CoA Carboxylase 1 (ACC1, TOFA), FASN (TVB3166), FAO (etomoxir), LD biogenesis (Diacylglycerol Acyltransferase 1 and 2, DGAT1 and DGAT2, inhibitors) or lipid mobilization from LD (Adipose Triglyceride Lipase, ATGL, inhibitor, ATGListatin) showed no significant difference between 67NR and 4T1 cells (Fig
Because of their size and structure, many can work precisely at a cellular level, often mimicking natural messenger molecules like hormones or neurotransmitters
Lyophilized peptide: date purchased
[DOI] [PMC free article] [PubMed] [Google Scholar] 117.Pham N.T.N., Huynh C.T.N., Nguyen A.T.T., Ho C.Q., Duong L.M., Bui D.T., Nguyen H.H